DNTH Trading Analysis - 11/06/2026 04:42 PM — TRU-SENTIMENT

DNTH (Dianthus Therapeutics Inc. Common Stock) at $86.10. True Sentiment Balanced, delta 40-60 call 0% / put 0%, call $0 vs put $0. RSI 79.7.

TRU-SENTIMENT · DeltaNeutral

DNTH Trading Analysis - 11/06/2026 04:42 PM — TRU-SENTIMENT

Options chain · Stock chart · Baseline chart

DNTH (Dianthus Therapeutics Inc. Common Stock) at $86.10. True Sentiment Balanced, delta 40-60 call 0% / put 0%, call $0 vs put $0. RSI 79.7.

Symbol
DNTH
Price
$86.10
Article bias (separate from True Sentiment)
neutral
Conviction
low
Published
2026-11-06 16:42:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

Per True Sentiment Options data for 2026-11-06: call dollar volume $0.00, put dollar volume $0.00, total $0.00, 0 contracts, sentiment "Balanced". Filter ratio 0.0% of 430 analyzed options met delta 40-60.

Call vs put conviction: no directional flow captured. Pure directional positioning suggests no near-term bias. Divergence: technicals show upside momentum (RSI 79.74, price > SMA 20) while options flow is neutral — sentiment not confirming technical strength.

Note: Options flow shows no delta 40-60 conviction; balanced read only.

Key Statistics: DNTH

$86.03 +3.38%
52-Week Range
$33.85 - $117.88
Market Cap
$4.81B
P/E (TTM)
3.20
PEG Ratio
N/A
Beta
0.03
Next Earnings
N/A
Avg Volume
$470,606
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

P/E (trailing)3.20
EPS (trailing 12 mo)$-4.15
Market cap$4.81B
Shares outstanding55.9M

Dividend

Dividend yield0.00%

Risk & range

Beta0.03
52-week low$33.85
52-week high$117.88
Historical volatility38.5%

Ownership & trading

Institutional ownership83.4%
Average daily volume1.0M sh

Reported figures; no analyst estimates.


📈 Analysis

News Headlines & Context

The following recent context items are provided from general knowledge and are separated from the data-driven analysis below.

  • DNTH (Dianthus Therapeutics) reported Q3 2026 pipeline progress in its complement-targeted monoclonal antibody programs, with analysts noting upcoming Phase 2 readouts as a potential catalyst.
  • Biotech sector saw broad volatility in late October 2026 amid FDA delay rumors, though no DNTH-specific action was confirmed.
  • Institutional ownership remained elevated near 83%, suggesting continued large-cap biotech interest despite price weakness from September highs.
  • No confirmed earnings date within the next 25 days was identified; next fiscal year end is Dec 2025 per fundamentals, with no near-term corporate event flagged.
  • Headlines imply a wait-and-see posture; this aligns with the balanced options sentiment and neutral technical bias observed in the embedded data.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for DNTH:

  • Trailing P/E is listed at 3.20, but trailing EPS is negative at -4.15, indicating the P/E is non-meaningful for profitability assessment.
  • Forward P/E, PEG ratio, price-to-book, total revenue, revenue growth, profit margins, ROE, and debt-to-equity are all null — no margin or growth trend can be derived.
  • Market cap is $4,812,002,020.00 with shares outstanding of 55,934,000.00 and institutional ownership at 83.41%.
  • Beta is 0.03 (very low systematic risk), dividend yield 0.00%, historical volatility 38.46%.
  • 52-week range: high $117.88, low $33.85. Current price $86.44 is below the midpoint, reflecting recovery off lows but far from highs.
  • Analyst consensus, target mean price, and recommendation key are null — no street bias available.
  • Fundamentals show a low-beta, institution-heavy profile with negative earnings; this diverges from the positive short-term technical momentum (RSI 79.74) seen in the data.

Current Market Position

Current price per indicators is $86.44 (2026-11-06 close $86.44). From daily history, DNTH closed at $83.22 on 2026-11-05 and $86.44 on 2026-11-06, a gain of $3.22 (3.87%).

Minute bars (2026-11-05 09:30 to 2026-11-06 15:55) show open $85.87 on Nov 5, intraday low $80.34 Nov 5, then recovery to $87.44 high on Nov 6 before fading to $86.10 at 15:55. Final 5 bars on Nov 6 drifted from $87.14 to $86.10 on rising volume (34,066 at last bar), suggesting late-session selling pressure.

Support
$80.34
Resistance
$87.44
20-day SMA
$79.57
50-day SMA
$90.03
30d Low
$69.43

Technical Analysis

Technical Indicators

Current Price
$86.44
SMA 5
$83.84
SMA 20
$79.57
SMA 50
$90.03
RSI 14
79.74
MACD
-1.22
Signal
-0.97
Histogram
-0.24
BB Upper
$86.87
BB Lower
$72.27
ATR 14
$3.92

Price is above SMA 5 ($83.84) and SMA 20 ($79.57) but below SMA 50 ($90.03) — short-term bullish alignment, longer-term bearish. No golden cross; SMA 5 > SMA 20 confirms near-term uptrend. RSI 79.74 shows strong momentum but near overbought (>70). MACD -1.22 below signal -0.97 with negative histogram -0.24 indicates bearish momentum persistence despite price recovery. Bollinger upper $86.87; price $86.44 is at band edge (expansion). 30-day range high $91.24, low $69.43; price at 56.7% of range.

True Sentiment Analysis (Delta 40-60 Options)

Per True Sentiment Options data for 2026-11-06: call dollar volume $0.00, put dollar volume $0.00, total $0.00, 0 contracts, sentiment "Balanced". Filter ratio 0.0% of 430 analyzed options met delta 40-60.

Call vs put conviction: no directional flow captured. Pure directional positioning suggests no near-term bias. Divergence: technicals show upside momentum (RSI 79.74, price > SMA 20) while options flow is neutral — sentiment not confirming technical strength.

Note: Options flow shows no delta 40-60 conviction; balanced read only.

Key Price Levels (observational only)

Support (Nov 5 low)
$80.34
Resistance (Nov 6 high)
$87.44
BB Lower
$72.27
SMA 50
$90.03
30d High
$91.24

Interactive charts load with JavaScript. This text is the crawlable summary.